Education
About Us
Working with TipRanks
Follow Us
Quantum-Si (QSI)
NASDAQ:QSI
Top Page
Quantum-Si
(NASDAQ:QSI)
46Neutral
Positive Factors
International Expansion
The company emphasized expansion into the international market with 18 international distribution partners to date, which could provide opportunities for revenue growth.
Partnerships
The recent partnership with Avantor is expected to provide support to grow sales in the biopharma sector.
Product Innovation
The company remains on track to launch the new proteomics platform, Proteus, featuring hardware and software enhancements for ultrarapid sequencing and high sample throughput.
Negative Factors
Financial Performance
The company reported total revenues of $808K, lower than consensus estimated revenue of $960K for 1Q25.
Funding Uncertainty
Uncertainty regarding NIH funding could continue to impact the academic research market.
Market Penetration Challenges
It may take significant time before QSI can penetrate the protein sequencing opportunity.
Quantum-Si (QSI) vs. S&P 500 (SPY)
Market Cap
$271.05M
Dividend YieldN/A
Average Volume (3M)4.06M
Price to Earnings (P/E)―
Beta (1Y)2.85
Revenue Growth167.94%
EPS Growth-3.66%
CountryUS
Employees149
SectorHealthcare
Sector Strength41
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.11
Shares Outstanding163,207,090
10 Day Avg. Volume6,097,180
30 Day Avg. Volume4,064,601
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)0.86
Price to Sales (P/S)0.00
P/FCF Ratio-2.50
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue23.40
Enterprise Value/Gross Profit360.80
Enterprise Value/Ebitda-0.53
Forecast
1Y Price Target
$2.83Price Target Upside91.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Quantum-Si Business Overview & Revenue Model
Company DescriptionQuantum-Si (QSI) is a biotechnology company focused on revolutionizing the field of proteomics through its proprietary semiconductor chip-based technology. The company operates within the life sciences sector, providing innovative tools for protein sequencing and analysis. Quantum-Si's core products include next-generation protein sequencing platforms designed to deliver precision and scalability in protein identification and quantification, catering to researchers and clinicians seeking to advance their understanding of proteomics and its applications in healthcare and scientific research.
How the Company Makes MoneyQuantum-Si generates revenue primarily through the sale of its protein sequencing platforms and related consumables. The company's business model is centered around providing cutting-edge technology that enables more accurate and efficient protein analysis, which is crucial for drug development, diagnostics, and personalized medicine. In addition to direct product sales, Quantum-Si may also engage in strategic partnerships and collaborations with academic institutions, pharmaceutical companies, and research organizations, which can lead to additional revenue streams through joint development agreements and technology licensing. Service contracts and maintenance agreements for their platforms also contribute to the company's earnings.
Quantum-Si Financial Statement Overview
Summary
Quantum-Si shows strong revenue growth but continues to face significant profitability challenges with negative margins and net losses. The balance sheet is robust with low leverage, but the company struggles to turn equity into profit. Cash flow remains a concern, with continued negative free cash flow, indicating ongoing operational and financial challenges.Income Statement
The company has shown strong revenue growth from $1.08 million in 2023 to $3.06 million in 2024, a significant improvement. However, gross profit margin is low at 52.33%, and the company is still operating at a substantial net loss of $101 million, resulting in a negative net profit margin of -3303.83%. EBIT and EBITDA margins are also deeply negative, indicating ongoing operational challenges.30
Negative
Balance Sheet
Quantum-Si maintains a strong equity position with a debt-to-equity ratio of 0.06, indicating low financial leverage. The equity ratio is high at 86.89%, suggesting a strong balance sheet. However, the company still reports significant net losses, impacting return on equity, which is negative at -46.89%. This indicates inefficiencies in using equity to generate profit.45
Neutral
Cash Flow
Operating cash flow is negative at -$87.8 million, reflecting ongoing operational cash strains. There has been a slight improvement in free cash flow over the years, but it remains negative at -$92.4 million. The operating cash flow to net income ratio is 0.87, showing that cash flow is closely tracking net income losses, which is a concern.40
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 3.06M | 1.08M | 0.00 | 0.00 | 0.00 | Gross Profit |
| 1.60M | 488.00K | -2.58M | -1.04M | -894.00K | EBIT |
| -108.58M | -111.17M | -123.84M | -96.91M | -36.69M | EBITDA |
| -108.58M | -91.80M | -129.86M | -95.87M | -35.80M | Net Income Common Stockholders |
| -101.01M | -95.96M | -141.04M | -88.95M | -36.61M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 209.60M | 257.74M | 351.31M | 471.30M | 36.91M | Total Assets |
| 247.87M | 298.25M | 391.49M | 503.23M | 40.59M | Total Debt |
| 12.95M | 15.30M | 17.45M | 8.08M | 1.75M | Net Debt |
| -36.29M | -118.56M | -66.87M | -27.71M | -35.16M | Total Liabilities |
| 32.45M | 26.63M | 32.78M | 26.19M | 4.50M | Stockholders Equity |
| 215.42M | 271.62M | 358.71M | 477.03M | 36.09M |
| Cash Flow | Free Cash Flow | |||
| -92.38M | -99.31M | -101.30M | -72.58M | -33.03M | Operating Cash Flow |
| -87.80M | -94.04M | -90.56M | -66.81M | -32.57M | Investing Cash Flow |
| -32.67M | 143.43M | 137.19M | -450.94M | -461.00K | Financing Cash Flow |
| 35.88M | 149.00K | 1.91M | 516.63M | 37.01M |
Quantum-Si Technical Analysis
Positive
1.48
Price Trends
1.28
Positive
1.72
Negative
1.36
Positive
Market Momentum
0.06
Negative
55.72
Neutral
67.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QSI, the sentiment is Positive. The current price of 1.48 is above the 20-day moving average (MA) of 1.29, above the 50-day MA of 1.28, and above the 200-day MA of 1.36, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 55.72 is Neutral, neither overbought nor oversold. The STOCH value of 67.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QSI.
Quantum-Si Risk Analysis
Quantum-Si disclosed 67 risk factors in its most recent earnings report. Quantum-Si reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Quantum-Si Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $290.39M | ― | -41.31% | ― | ― | -7.93% | |
58 Neutral | $121.86M | ― | -24.73% | ― | -1.02% | -8.59% | |
52 Neutral | $5.15B | 3.02 | -44.64% | 2.83% | 16.44% | -0.47% | |
47 Neutral | $234.49M | ― | -30.47% | ― | ― | -22.66% | |
46 Neutral | $271.05M | ― | -40.23% | ― | 167.94% | -3.66% | |
46 Neutral | $246.93M | ― | 322.49% | ― | -30.66% | 36.48% | |
41 Neutral | $103.95M | ― | -30.93% | ― | ― | -1.20% |
* Healthcare Sector Average
Performance Comparison
QSI
Quantum-Si
1.41
-0.36
-20.34%
NAUT
Nautilus Biotechnolgy
0.80
-2.04
-71.83%
FHTX
Foghorn Therapeutics
4.21
-1.79
-29.83%
AVIR
Atea Pharmaceuticals
2.74
-0.86
-23.89%
CMPX
Compass Therapeutics
2.11
0.51
31.87%
SEER
Seer
2.07
-0.01
-0.48%
Quantum-Si Earnings Call Summary
Earnings Call Date:May 15, 2025
(Q1-2025)
| % Change Since: 0.00%|
Next Earnings Date:Aug 11, 2025
Earnings Call Sentiment Neutral
The earnings call reflects significant revenue growth and strong international performance, supported by the successful launch of the Platinum Pro system and advancements in R&D. However, challenges persist in the U.S. academic market due to funding uncertainties and increased operating expenses. Despite potential tariff impacts, the company sustains financial stability with a lengthy cash runway.Q1-2025 Updates
Positive Updates
Significant Revenue Growth
First quarter revenue of $842,000 represented an 84% increase over the first quarter of 2024.
Strong International Performance
Exited the first quarter with 23 international distribution partners; international business performed well with continued interest from potential customers across all territories.
Launch of Platinum Pro System
Successfully launched the Platinum Pro system and completed first customer sales.
Advancements in R&D
On track for the launch of version 4 Sequencing Kit in Q3 2025 and progress in library preparation and Proteus development programs.
Financial Stability
Cash and cash equivalents and investments in marketable securities totaled $232.6 million, providing a runway into the second half of 2027.
Negative Updates
U.S. Academic Market Slowdown
Significant slowdown in new instrument purchases in the U.S. academic market due to uncertainties related to NIH funding and indirect cost caps.
Operating Expenses Increase
Total operating expenses for Q1 2025 were $25.6 million, up from $23.6 million in Q1 2024, despite efforts to manage costs.
Impact of Tariffs
Potential impacts from tariffs on inventory acquisition costs and sales channels outside the U.S. being monitored.
Company Guidance
During the first quarter of 2025, Quantum-Si reported revenue of $842,000, marking an 84% increase over the same period in 2024, despite facing challenges due to market uncertainties related to NIH funding. The gross profit for the quarter was $486,000, with a gross margin of 58%. Operating expenses were reported at $25.6 million under GAAP and $22.9 million when adjusted, while the company maintained cash and cash equivalents totaling $232.6 million as of March 31, 2025. Quantum-Si aims to keep adjusted operating expenses at $103 million or less for the year. The company remains focused on its three primary goals: accelerating commercial adoption, delivering on its innovation roadmap, and preserving financial strength, with a strong emphasis on expanding opportunities in the pharma and biotech sectors to mitigate the impact of the NIH-related uncertainties.Quantum-Si Corporate Events
Product-Related AnnouncementsBusiness Operations and Strategy
Quantum-Si Updates Corporate Strategy in Proteomics
Positive
Apr 10, 2025
On April 10, 2025, Quantum-Si Incorporated updated its corporate presentation, highlighting its strategic positioning in the expanding proteomics market. The company’s Proteus platform, expected to launch in the second half of 2026, aims to revolutionize proteomics research by offering single-molecule, top-down, and bottom-up methods. Quantum-Si’s technology is designed to address the complexities of proteomics analysis and is anticipated to transform the field from a complementary to a primary technology in research. The company’s advancements are expected to accelerate commercial adoption, evidenced by a 183% year-over-year growth.
Spark’s Take on QSI Stock
According to Spark, TipRanks’ AI Analyst, QSI is a Neutral.
Quantum-Si’s score reflects its robust revenue growth and strategic advancements, but it is weighed down by ongoing profitability challenges and negative cash flows. The stock’s technical indicators suggest current bearish momentum, and its valuation poses challenges due to a lack of profitability. The earnings call offered a positive outlook, but significant operational and market challenges remain.
To see Spark’s full report on QSI stock, click here.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.